uniQure (NASDAQ:QURE) Shares Gap Down – What’s Next?

Shares of uniQure N.V. (NASDAQ:QURE) gapped down before the market opened on Thursday . The stock had previously closed at $24.87, but opened at $20.90. uniQure shares last traded at $18.5670, with a volume of 4,022,746 shares traded.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Wolfe Research initiated coverage of uniQure with a “peer perform” rating — an analyst view that is not a clear bullish catalyst and may be seen as neutral to slightly negative given the company’s recent volatility. Wolfe Research story
• Neutral Sentiment: Analyst roundup coverage (5 analysts assessed uniQure) provides additional research flow but no clear consensus upgrade that would offset recent legal and regulatory pressure. Analyst summary
• Negative Sentiment: A securities‑fraud class action has been filed covering purchases between Sept. 24, 2025 and Oct. 31, 2025; multiple national plaintiff firms (including Berger Montague, Kessler Topaz, Pomerantz, Rosen, Levi & Korsinsky, Faruqi & Faruqi, Bragar Eagel & Squire and others) are soliciting lead‑plaintiff applications with an April 13, 2026 deadline — increasing legal risk, potential discovery/costs, and short‑term selling pressure. Berger Montague filing
• Negative Sentiment: Coverage and alerts from many plaintiff firms and services (ClaimsFiler, Bernstein Liebhard, Kahn Swick & Foti, etc.) amplify the publicity around the suit and the April 13 lead‑plaintiff deadline — typically a near‑term headwind for stocks as institutional and retail holders react. Bernstein Liebhard alert
• Negative Sentiment: Media reporting ties the class action to an FDA approval delay and an earlier ~49% stock drop — an allegation that, if litigated, can raise uncertainty about management disclosures and regulatory timing. GazetteXtra report

Analyst Upgrades and Downgrades

QURE has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research report on Wednesday, January 14th. Benchmark reissued a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Wolfe Research initiated coverage on shares of uniQure in a research report on Monday. They issued a “peer perform” rating for the company. Finally, Royal Bank Of Canada lowered their price objective on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average target price of $58.33.

uniQure Stock Performance

The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -3.99 and a beta of 0.66. The stock’s 50-day moving average is $23.76 and its 200-day moving average is $29.67.

Insider Buying and Selling at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Virtus Investment Advisers LLC boosted its position in uniQure by 91.6% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 6,520 shares during the last quarter. SummitTX Capital L.P. lifted its stake in shares of uniQure by 386.3% in the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after purchasing an additional 22,010 shares during the period. Suvretta Capital Management LLC bought a new stake in shares of uniQure during the 4th quarter valued at about $29,116,000. Readystate Asset Management LP acquired a new stake in uniQure during the fourth quarter worth approximately $8,652,000. Finally, Orbimed Advisors LLC increased its holdings in uniQure by 60.8% in the fourth quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company’s stock worth $17,646,000 after purchasing an additional 278,900 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.